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Pathway-based association methods have been proposed to be an effective approach in
identifying disease genes, when single-marker association tests do not have sufﬁcient
power. The analysis of quantitative traits may be beneﬁted from these approaches, by
sampling from two extreme tails of the distribution. Here we tested a pathway associa-
tion approach on a small genome-wide association study (GWAS) on 653 subjects with
extremely high high-density lipoprotein cholesterol (HDL-C) levels and 784 subjects with
low HDL-C levels.We identiﬁed 102 genes in the sterol transport and metabolism pathways
that collectively associate with HDL-C levels, and replicated these association signals in an
independent GWAS. Interestingly, the pathways include 18 genes implicated in previous
GWAS on lipid traits, suggesting that genuine HDL-C genes are highly enriched in these
pathways. Additionally, multiple biologically relevant loci in the pathways were not detected
by previous GWAS, including genes implicated in previous candidate gene association stud-
ies (such as LEPR, APOA2, HDLBP, SOAT2), genes that cause Mendelian forms of lipid
disorders (such as DHCR24), and genes expressing dyslipidemia phenotypes in knock-
out mice (such as SOAT1, PON1). Our study suggests that sampling from two extreme
tails of a quantitative trait and examining genetic pathways may yield biological insights
from smaller samples than are generally required using single-marker analysis in large-
scale GWAS. Our results also implicate that functionally related genes work together to
regulate complex quantitative traits, and that future large-scale studies may beneﬁt from
pathway-association approaches to identify novel pathways regulating HDL-C levels.
Keywords: GWAS, lipid, HDL-C, pathway analysis, cholesterol, sterol transport, sterol metabolism, genetic
association
INTRODUCTION
Genome-wide association studies (GWAS) have been very success-
ful in identifying genes or loci that are associated with complex
diseases or quantitative traits. However, for most GWAS, the col-
lection of known loci explains only a minor fraction of disease
heritability (Maher, 2008; Manolio et al., 2009). Since most GWAS
are not powered to detect themajority of genuinely associated loci,
researchers could expand sample size indeﬁnitely in an attempt to
ﬁndmore associated loci; however, this approachhas its limitations
as the GWAS are likely to have diminishing returns. That is, after
the ﬁrst few loci (presumably more readily detectable with larger
effect sizes) have been identiﬁed and replicated, the remaining loci
will be more and more difﬁcult to ﬁnd as they will have much
smaller effect sizes (Goldstein, 2009). An alternative approach to
detect trait-associated loci in GWAS, which can provide comple-
mentary information to single-marker analysis, is a pathway-based
approach, which examines whether test statistics for related genes
in the same pathway are consistently associated with a disease trait
under study (Wang et al., 2010).
There have been a few published examples demonstrating the
power and effectiveness of pathway-wide association approaches
for several diseases. We have previously developed a pathway asso-
ciation approach (Wang et al., 2007), by adopting the Gene Set
Enrichment Analysis (Subramanian et al., 2005) strategies, but
with appropriate modiﬁcations to account for the linkage dise-
quilibrium between SNP markers, the different sizes of genes and
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pathways. This approach has been successfully applied to uncover
association between the IL12/IL23 pathway and Crohn’s disease
(Wang et al., 2009a), the involvement of cell adhesion molecules
in autism spectrum disorders (Wang et al., 2009b), as well as the
WNT-signaling pathway in Type 2 Diabetes (T2D) (Perry et al.,
2009). Additionally, Lesnick et al. (2007) have demonstrated that
SNPs in the candidate pathway (axon guidance) collectively pre-
disposed to a Parkinson’s disease, even though no individual SNP
reaches genome-wide signiﬁcance level. Dinu et al. (2007) applied
a pathway approach and discovered thatmultiple complement fac-
tor pathway genes, in additional to complement factor H (a well
known susceptibility locus), are associatedwith risk for developing
age-related macular degeneration (AMD). Torkamani et al. (2008)
applied a pathway-based approach to analyze the Wellcome Trust
Case Control Consortium (WTCCC) data sets, and discovered
numerous pathways implicated in disease predisposition, many
of which have long been assumed to contain polymorphic genes
that lead to disease predisposition. Askland et al. (2009) analyzed
GWAS data sets on bipolar disorder using a pathway association
approach,and implicated genesmediating ion channel activity and
synaptic neurotransmission. Holmans et al. (2009) also described
a pathway approach and applied it on meta-analysis of bipolar
disorder, and implicated a collection of genes involved in the
modulation of transcription and cellular activity. Furthermore,
several recent studies have focused on incorporating biological
network structure into the analysis of GWAS (Pan, 2008; Baranzini
et al., 2009). Collectively, all these studies show that pathway-based
approaches can be applied to GWAS data sets to gain insights into
disease susceptibility mechanisms, and to provide enhanced or
complementary information to the conventional single-marker
analysis.
Unlike previous disease studies, our current study focused on
a quantitative trait, plasma levels of high-density lipoprotein cho-
lesterol (HDL-C), to examine whether pathway-based approaches
can be effective in enriching a group of truly associated genes.
HDL-C, together with low-density lipoprotein cholesterol (LDL-
C) and triglyceride (TG), are three major lipid phenotypes in the
human serum. Lipid levels are heritable traits that are strongly
associated with cardiovascular risk, therefore they are widely
measured in clinical practice. Lipid measures represent excellent
secondary phenotypes for genetic investigation by many GWAS,
and relatively large sample sizes can be obtained to study these
traits. Three large-scale GWAS have been reported to identify
genetic loci associated with lipid traits: Kathiresan et al. (2009)
conducted GWAS screens in 19,840 individuals and replication
in up to 20,623 individuals, and identiﬁed 30 loci (36 trait-loci
associations) controlling HDL-C, LDL-C, or TG levels. Sabatti
et al. (2009) have assayed a birth cohort from a founder popu-
lation with ∼4,500 subjects, and identiﬁed 17 trait-loci associa-
tions for lipid levels. Aulchenko et al. (2009) analyzed 16 Euro-
pean population cohorts with ∼20,000 subjects and identiﬁed
22 trait-loci associations on lipid traits. More recently, Teslovich
et al. (2010) have published an even larger meta-analysis on lipid
traits involving over 100,000 subjects. Despite these early suc-
cesses, a more complete ensemble of lipids genes is needed for
better understanding of the gene networks involved, and the cur-
rent successes probably merely represent the start of a long road
(Edmondson and Rader, 2008; Holleboom et al., 2008) for the fol-
lowing reasons: First, among genes that cause Mendelian disorders
of lipid traits, only a subset of them have been identiﬁed in GWAS
(Edmondson and Rader, 2008). Second, multiple candidate genes
believed to affect HDL-C levels based on preclinical models have
not yet been identiﬁed in GWAS for HDL-C. Finally, the collection
of HDL-C genes identiﬁed in GWAS only explains a minor frac-
tion of inter-individual variability in lipoprotein levels (Kathiresan
et al., 2009). Therefore, it is likely that many more genes regulating
HDL-C levels remain to be discovered.
In this study, we applied a pathway-based association approach
on aGWAS for the purpose of identifying genes regulatingHDL-C
levels. The study is distinct from previous GWAS on lipids in that
it was originally designed and ascertained as a case/control study,
so the study participants have either extremely high or low HDL-
C levels but without syndromic dyslipidemia features. Although
the initial single-marker association analysis identiﬁed only one
well known locus that signiﬁcantly associates with HDL-C, the
pathway-based association approach resulted in ∼100 loci that
potentially associate with HDL-C, including multiple previously
known lipid loci. We further validated some of the novel ﬁndings
through literature survey of previously known Mendelian forms
of lipid disorders, previously published candidate gene associa-
tion studies, as well as the examination of metabolic phenotypes
of gene knockout mice maintained by the Jackson laboratory. Our
study has signiﬁcant implications for the study of quantitative
traits and the analysis of GWAS data: First, it demonstrated that a
modest case/control data set sampling from two extreme tails of a
quantitative trait can be very useful in identifying genuinely asso-
ciated genes. Second, it illustrated that pathway-wide association
approaches could provide biological insights that are not read-
ily available from single-marker analysis on orders of magnitude
larger sample sizes.
MATERIALS AND METHODS
STUDY PARTICIPANTS
Discovery cohort
Cases and control subjects were ascertained for the purpose of
identifying genetic variation regulating HDL-C levels. All study
participants were self-declared to be of European ancestry, and
were genotyped on the Affymetrix Genome-wide Human SNP 6.0
arrays. The “cases” were deﬁned as persons with HDL-C levels
>94th percentile for age and gender. The control subjects were
deﬁned as persons with HDL-C <25th percentile for age and gen-
der. Based on the whole-genome genotyping data, we performed
multi-dimensional scaling analysis on a set of independent SNP
markers (Figure S1 in Supplementary Material), to ensure that
only subjects of genetically inferred European ancestry were used
in analysis. We also removed subjects with call rates of SNPs less
than 95%. Additionally, we have removed pairs of subjects with
cryptic relatedness, as deﬁned by identity-by-descent score higher
than 0.2. The ﬁnal data set for association analysis included a total
of 653 cases and 784 control subjects with 681,050 SNP mark-
ers. The genomic control inﬂation factor was 1.057, indicating
that cases and control subjects were well matched and that no
systematic batch effects were present.
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Replication cohort
The replication cohort was compiled from PennCATH and Med-
Star, two ongoing GWAS on coronary artery disease, which were
previously described in detail (Myocardial Infarction Genetics
Consortium et al., 2009). The PennCATH study is a University
of Pennsylvania Medical Center based angiographic study of over
3,800 subjects that has beenusedpreviously for replicationof novel
genes and risk factors for atherosclerotic cardiovascular disease
and T2D (Helgadottir et al., 2006; Steinthorsdottir et al., 2007).
The MedStar study is a Washington Hospital Center based angio-
graphic study of 1,500 subjects speciﬁcally designed for biomarker
and genetic association studies of acute and chronic coronary
atherosclerosis. Since the PennCATH and MedStar samples were
genotyped together at the same site and were analyzed by identical
procedures, to improve power to detect association, we combined
the two data sets together. To deﬁne HDL-C case–control status,
the subjects were dichotomized by sex-speciﬁc cutoff points: those
subjects with HDL-C higher than 80% percentile were regarded as
“cases” and those with HDL-C levels lower than 20% percentile
were regarded as control subjects. The thresholds differ from
the discovery cohort, because the discovery cohort is speciﬁcally
designed and ascertained for studying high HDL levels, whereas
the PennCATH and MedStar were not ascertained in this man-
ner. Subjects who participated in the discovery cohort were not
included in the replication cohort. Through these criteria, a total
of 496 cases and 373 control subjects were included in the analysis.
Ethics statement
All subjects have been enrolled in a University of Pennsylva-
nia or Washington Hospital Institutional Review Board approved
protocol, and all subjects gave written informed consent.
PATHWAY ASSOCIATION ANALYSIS
The method for pathway-based association test was previously
described in detail elsewhere (Wang et al., 2007, 2009a). Brieﬂy,
we assign each SNP to the overlapping gene/genes, or its closest
gene (subject to a distance constraint) in the genome if it does not
overlap with a gene. For each gene,we assigned the highest statistic
value among all SNPs mapped to the gene as the statistic value of
the gene. For all the N genes that are represented by SNPs in the
GWAS,we sorted their statistic values from the largest to the small-
est, denoted by r (1), . . ., r (N ). For any given gene set S composed of
NH genes, we then calculated a weighted Kolmogorov–Smirnov-
like running sum statistic(Hollander andWolfe, 1999) that reﬂects
the overrepresentation of genes within the set S at the top of the
entire ranked list of genes in the genome,
ES(S) = max
1jN
⎧⎨
⎩
∑
Gj∗∈S,j∗j
∣∣r(j∗)
∣∣p
NR
−
∑
Gj∗ /∈S,j∗j
1
N − NH
⎫⎬
⎭
where NR = ∑
Gj∗∈S,
∣∣r(j∗)
∣∣p and p (default value= 1) is a para-
meter that gives higher weight to genes with extreme statistic
values. To adjust for differences in gene size (hence the differ-
ent number of SNPs located within/nearby each gene), as well as
the linkage disequilibrium between SNPs within the same gene,
we conducted a two-step correction procedure. In the ﬁrst step,
we permuted the disease labels of all samples ensuring the same
number of individuals in each phenotype group for case–control
studies. During each permutation (denoted byπ), we repeated the
calculation of enrichment score as described above as ES(S,π). In
the second-step,we calculatednormalized enrichment score (NES)
as a Z -score, deﬁned as [ES(S)−mean(ES(S, π))]/SD[ES(S, π)],
so that different gene sets are directly comparable to each other.
The P-value can be calculated from the π permutations, and a
false discovery rate (FDR) procedure can be used to control the
fraction of expected false positive ﬁndings below a certain thresh-
old (Reiner et al., 2003). For a gene set, let NES∗ denote the NES
in the observed data. The FDR is calculated as
(
% of all (S, π) with NES(S, π)  NES∗
)
/(
% of observed S with NES(S)  NES∗
)
.
Alternatively, we also calculated the FWER P-value as the fraction
of all permutations whose highest NES score in all gene sets are
higher than theNES* for a given gene set. For the discovery cohort,
a total of 10,000 phenotype permutation cycles were used so that
a more accurate P-value can be calculated for each pathway; for
replication cohort, 1,000 phenotype permutation cycles were used.
The software implementing this method was made freely avail-
able at http://www.openbioinformatics.org/gengen. The current
software uses chi-square test statistics for association, so it can-
not incorporate covariates in the analysis. The software package
included pathway deﬁnitions for the three pathway collections
(KEGG, BioCarta, GO) used in the study, as well as library
ﬁles mapping SNP identiﬁers to gene names for the Affymetrix
Genome-wide Human SNP 6.0 array. The pathway collections
were accessed and assembled on March 03, 2008. These default
library ﬁles, as well as all default parameters in the software, were
used in our pathway association analysis.
RESULTS
SINGLE-MARKER AND PATHWAY ASSOCIATION ANALYSIS ON HDL-C
LEVELS
We examined a previously unpublished cohort on HDL-C lev-
els (discovery cohort, Table 1), genotyped on the Affymetrix
Genome-wideHuman SNP 6.0 arrays. Unlike other disease studies
that investigated HDL-C levels as an additional/secondary pheno-
type for investigation, this cohort consists of “cases”with extremely
high HDL-C levels and “control” subjects with low HDL-C levels
(seeMaterial andMethods). One locus on 16q13 reached genome-
wide signiﬁcance levels of P < 5× 10−8 (Figure 1), with the most
signiﬁcant SNP being rs1532625 (P = 6.8× 10−12, OR= 1.68)
within CETP (cholesteryl ester transfer protein). This locus was
a well-established HDL-C locus before the GWAS era (Koizumi
et al., 1985; Kurasawa et al., 1985; Inazu et al., 1990). There-
fore, through single-marker association analysis, no novel lipid
genes were identiﬁed that met genome-wide signiﬁcance criterion,
though we were able to replicate several loci from other published
studies on lipid levels (Table S1 in Supplementary Material). Alto-
gether, these single-marker association results testiﬁed the high
quality of the phenotype data, anddemonstrated the unique power
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Table 1 | The most significantly associated pathways in the discovery GWAS data set.
Pathway ID Description Number of genes Z -score P -value FDR Replication P -value
GO0016125 Sterol metabolic process 89 3.665 <0.0001 0.083 0.029
GO0008202 Steroid metabolic process 140 3.608 0.0004 0.052 0.17
GO0015918 Sterol transport 25 3.475 <0.0001 0.056 0.083
GO0006096 Glycolysis 45 3.077 0.0007 0.161 0.60
Insulin pathway Insulin Signaling Pathway 22 2.642 0.0039 0.484 0.83
hsa00960 Alkaloid biosynthesis II 20 2.518 0.0008 0.569 0.50
hsa04360 Axon guidance 128 2.41 0.0085 0.653 0.81
FIGURE 1 | Manhattan plot of the single-marker association analysis on the discovery cohort. Except CETP on 16p13.3, single-marker analysis failed to
identify any locus reaching genome-wide signiﬁcance (P < 5× 10−] ).
of case/control data set that samples from extreme tails of normal
distributions on a quantitative trait.
To screen for novel biological pathways or collections of func-
tionally related genes that associate with HDL-C levels, we next
applied a pathway-based association approach (Wang et al., 2007)
on this GWAS data set,with the same set of subjects and SNPs used
in single-marker association analysis. This pathway association
method permutes the case/control labels a large number of times,
and for each permuted data set, it re-calculates the association test
statistics for all SNP markers, and then assesses the signiﬁcance
of the pre-deﬁned pathways or sets of genes by comparing the
observed test statistics with the null distribution generated by the
permutations. The collection of pathways or gene sets analyzed in
the study was retrieved from the BioCarta (BioCarta, BioCarta-
Charting pathways of life), KEGG (Kanehisa et al., 2010) and level
4 of theGeneOntology (Ashburner et al., 2000) databases.We per-
formed 10,000 permutations and assessed a total of 568 pathways
passing size threshold (20–200 genes). We found that seven path-
ways were associated with HDL-C levels at a nominal P-value less
than 0.01 (Table 1), slightly more than expected by chance (5.68).
Among these pathways, four have false discovery rate (FDR) less
than 25%. However, we note that all genes in the “sterol metabolic
process” pathway belong to the “steroid metabolic process” path-
way as both were from the Gene Ontology collection (Figure S2
in Supplementary Material), therefore we excluded the “steroid
metabolic process”pathway from further discussion as it has lower
Z -score andP-value than its subset. The full list of genes and repre-
sentative SNPs for the sterol metabolism and transport pathways
were given in Figure S2 in Supplementary Material. To further
evaluate the sensitivity of the pathway analysis to the inclusion of
CETP – a well known HDL-C gene that showed genome-wide sig-
niﬁcance in our single-marker association analysis – we removed
CETP from the pathway analysis. This practice is similar to remov-
ing APOE from pathway analysis on Alzheimer’s disease (Jones
et al., 2010) or removing NOD2 from pathway analysis on Crohn’s
disease (Wang et al., 2009a). We still observed association signals
for the “sterol metabolic process” and “sterol transport” pathways
but with reduced signiﬁcance levels (P = 0.0011 and P = 0.007,
respectively), suggesting that the observed pathway associations
above were not due to the effect of CETP alone.
Similar to single-marker association tests, pathway-based asso-
ciation testsmay be susceptible to spurious associations, sowe next
sought to replicate the pathway ﬁndings using independent data
sets. Since the pathway association method requires phenotype
permutation of case/control status, we compiled a case–control
dataset (496 cases, 373 controls) from ongoing GWAS at Univer-
sity of Pennsylvania which have fasting lipid measures on some
study participants (see Materials and Methods). The replication
P-values for sterol metabolic process pathway and sterol trans-
port pathway are 0.029 and 0.083, respectively. These values do
not reach stringent levels of statistical signiﬁcance considering the
need to test two hypotheses, and this may be due to the lack of
power in the replication study.
ADDITIONAL EVIDENCE SUPPORTING PATHWAY ASSOCIATION
SIGNALS
Although our study demonstrated that a group of genes were col-
lectively associated with HDL-C levels, only one locus (CETP)
truly showed a genome-wide signiﬁcance signal in single-marker
association analysis. The Gene Ontology pathways were curated
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from heterogeneous data sources such as electronic annotation
from protein homology searches, so they may contain genes that
are not genuinely associated with HDL-C levels. Therefore, we
applied three complementary approaches, to search for additional
evidence supporting the role of a subset of genes in the pathways
in regulating HDL-C levels, and summarized the results in Table 2.
First, we examined the sterol transport and metabolism genes
in three independent GWAS [the Kathiresan et al. (2009) meta-
analysis, the Aulchenko et al. (2009) meta-analysis, the Sabatti
et al. (2009) study on founder populations), as well as the large-
scale Teslovich et al. (2010) meta-analysis. Among the 102 unique
genes (96 unique loci), genes in the sterol transport and metabo-
lism pathways, 9 and 15 loci were reported as genuine HDL-C loci
and/or LDL-C/TG loci in at least one of these publications, respec-
tively (Table 2). The abundance of previously known lipid genes
in the identiﬁed pathway therefore served as de novo conﬁrmation
supporting the biological relevance of the pathways. Additionally,
when examining previously published candidate gene associa-
tion studies, we found that multiple genes in the sterol trans-
port/metabolism pathway, such as LEPR,APOA2, SOAT2,HDLBP,
were previously associated with lipid levels (Table 2), albeit with
relatively small effect sizes and in some cases not replicated.
Second, we examined published literature on monogenic form
of lipid disorders, and determined whether any of the sterol trans-
port/metabolism genes have been previously associated with such
diseases. Interestingly,multiple additional genes, such as DHCR24
and APOA2, have never been implicated by GWAS on lipid traits,
but were identiﬁed as genuine lipid genes through the study of
rare forms of lipid disorders (Table 2). It is possible that no
common causal variants in these genes exist in European popula-
tions, or that the effect sizes of causal variants are too small to be
detected by the sample sizes used in previous studies. Nevertheless,
this fact implicates the complementary nature of pathway-based
association approach to single-marker association approach, and
supports the utility of the pathway-based approach in identifying
biologically relevant genes.
Third, we examined previous functional studies conducted on
model organisms, includingmouse knockout studies.Unlikemany
complex human diseases where genetic models are difﬁcult to
replicate or study in animal models, the lipid traits are easily mea-
surable and quantiﬁable, so they were almost always included in
knockout experiments, facilitating the functional study of lipid
genes. This analysis revealed multiple additional previously unre-
ported genes, including SOAT1, LEPR, and PON1, that had a
metabolic phenotype (increased or decreased cholesterol levels)
in knockout experiments (Table 2).
Altogether, the three complementary approaches presented
above resulted in the conﬁrmation of a prioritized set of genes that
have strong a prior evidence of playing a role in HDL-C regula-
tion. Although the sterol transport/metabolism pathways contains
102 genes, this particular subset of genes may represent a prior-
itized subset that are promising candidates to be investigated in
functional studies of lipid traits.
DISCUSSION
In this study, we performed pathway-based genome-wide asso-
ciation analysis on two GWAS data sets, and demonstrated that
a group of sterol transport and metabolism genes are collec-
tively associated with HDL-C levels. We further validated a
subset of these genes through examination of previously pub-
lished candidate gene association studies, known Mendelian
forms of lipid disorders, and known dyslipidemia phenotypes
in knockout mice. Compared to previously published large-scale
GWAS, our results supplied a richer list of additional candidate
genes regulating HDL-C levels, and demonstrated the enhanced
power of pathway-based association analysis on ﬁnding bio-
logically relevant genes. Given the relatively small sample size,
we were not able to identify previously unknown pathways as
being involved in regulation of HDL-C levels; however, the fact
that known pathways and genes are identiﬁed suggest that the
approach may be applicable to larger sample sets to identify novel
pathways.
The physiology of HDL metabolism results from the complex
interplay of multiple gene products including apolipoproteins,
enzymes, lipid transfer proteins, cellular transporters, and recep-
tors. Although the pathways identiﬁed in the study are intuitive in
a biological sense, caution should be exercised as some of the genes
within the pathways probably playmore important anddirect roles
than other genes in regulating HDL-C homeostasis. This explains
the rationale of our three-tiered prioritization approach to identify
subsets of HDL-C genes for future functional studies.
We also wish to discuss a few points related to sample ascer-
tainment scheme. One particular point is that all individuals in
the discovery cohort are ascertained from the general population
with extreme lipids measures, yet the individuals in the replication
cohort have CAD. HDL-C levels might be more disturbed by lipid
medications or other clinical factors in CAD patients. Therefore,
although it would be valid to use individuals with CAD for repli-
cation purposes, it would be most appropriate to make discoveries
from general population, to ensure that the data ascertainment
scheme does not bias the results (for example, pathways that asso-
ciate with CAD status rather than lipids levels). Another point
is that our study did not utilize a larger cohort and took a QTL
approach for the association analysis. It is expected that underﬁxed
genotyping budget, extreme phenotypes have greatly improved
power to detect associations due to increased odds ratio measures.
However, lipids measures are easily obtainable, so they represent
excellent secondary phenotypes available from many GWAS on
diverse phenotypes with large sample sizes. Therefore, we expect
that aQTLapproach for a very large cohortmay also have sufﬁcient
power to identify the implicated pathways.
Although the name “pathway” was used in our analysis, we
caution that the term merely refers to a collection of genes, rather
than an inter-connected biological process. The pathway-based
association analysis is borrowed from microarray data analysis,
where sets of related genes are combined into a single group
to examine the up or down-regulation of gene expression lev-
els for a group of genes that are consistent. Therefore, “pathway”
does not necessarily correspond to biologists’ understanding of
biological process, but rather a functional classiﬁcation of genes
based on a set of pre-deﬁned criteria. Our study used pathways
compiled from three resources, but we note that other pathway
collections could also be explored. Furthermore, we note that
pathways analyses have the potential to move beyond the so-called
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Table 2 | List of genes in the sterol transport/metabolism pathway with additional evidence of association with lipid traits.
Gene Locus Previous
GWAS
(HDL)
Previous
GWAS
(LDL/TG)
Teslovich
GWAS
(HDL)
Teslovich
GWAS
(LDL/TG)
Knockout
mouse
phenotype
Candidate
gene
association
Medelian
lipid
disorders
ELA3A 1p36.12
ELA3B
LDLRAP1 1p36.11 Yes Elevated LDL-C (Jones
et al., 2003)
Familial hypercholes-
terolemia (Garcia et al.,
2001; Soutar and
Naoumova, 2007)
NR0B2 1p36.11
STX12 1p35.3
DHCR24 1p32.3 No plasma or tissue choles-
terol (Wechsler et al., 2003)
Desmosterolosis
(Waterham et al., 2001)
PCSK9 1p32.3 Yes Yes Decreased plasma choles-
terol (Rashid et al., 2005)
Decreased LDL-C
and protection from
CAD (Cohen et al.,
2006)
Autosomal dominant hyper-
cholesterolemia (Abifadel
et al., 2003)
PRKAA2 1p32.2
ANGPTL3 1p31.3 Yes Yes Decreased plasma lipids
(Koishi et al., 2002)
LEPROT 1p31.3
LEPR Increased circulating cho-
lesterol level (JAX1) Sun et al. (2009)
HMGCS2 1p12
PMVK 1q22
FDPS 1q22
APOA2 1q23.3 Decreased HDL-C level
(JAX1) Chen et al. (2009)
Familial hypercholes-
terolemia modiﬁer (Takada
et al., 2002)
SOAT1 1q25.2 Increased circulating cho-
lesterol level (JAX1)
CYB5R1 1q32.1
APOB 2p24.1 Yes Yes Yes Embryonic lethal, heterozy-
gotes have decreased
plasma cholesterol (Huang
et al., 1995), hyopbetal-
ipoproteinemia (Homanics
et al., 1993)
Hypobetalipoproteinemia
(Young et al., 1987)
SNX17 2p23.3
ABCG8 2p21 Yes Yes Sitosterolemia (Klett et al.,
2004)
Sitosterolemia (Berge et al.,
2000)
INSIG2 2q14.2
HDLBP 2q37.3
Cánovasa et al.
(2009)
SCAP 3p21.31
CNBP 3q21.3
SC4MOL 4q32.3
PRKAA1 5p13.1
HMGCS1 5p12
HMGCR 5q13.3 Yes Yes
IL4 5q23.3
APOM 6p21.33 Yes Accumulation of large HDL
particles (Wolfrum et al.,
2005)
(Continued)
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Table 2 | Continued
Gene Locus Previous
GWAS
(HDL)
Previous
GWAS
(LDL/TG)
Teslovich
GWAS
(HDL)
Teslovich
GWAS
(LDL/TG)
Knockout
mouse
phenotype
Candidate
gene
association
Medelian
lipid
disorders
PPARD 6p21.31
TRERF1 6p21.1
CYP39A1 6p12.3
NPC1L1 7p13 Yes Increased cholesterol level
(JAX1)
PON1 7q21.3 Increased LDL-C level
(JAX1)
CAV1 7q31.2
LEP 7q32.1
AKR1D1 7q34
PRKAG2 7q36.1
INSIG1 7q36.2
CLN8 8p23.3
FDFT1 8p23.1
CYP7A1 8q12.1 Yes Nearly absent cholesterol
absorption (JAX1) Couture et al.
(1999), Wang et al.
(1998)
Hypercholesterolemia
(Pullinger et al., 2002)
CYP7B1 8q12.3 Elevated levels of 2 differ-
ent oxysterols in serum and
tissue (Li-Hawkins et al.,
2000)
SQLE 8q24.13
VLDLR 9p24.2
OPRS1 9p13.3
ABCA1 9q31.1 Yes Yes Yes Nearly absent HDL-C (Orso
et al., 2000)
Tangier disease (Bodzioch
et al., 1999; Brooks-Wilson
et al., 1999; Rust et al.,
1999)
CEL 9q34.2
RXRA 9q34.2
ABCA2 9q34.3
IDI2 10p15.3
IDI1 10p15.3
CUBN 10p13
CH25H 10q23.31
OSBPL5 11p15.4
CYB5R2 11p15.4
TM7SF2 11q13.1
DHCR7 11q13.4 Reduction of serum and tis-
sue cholesterol levels (Was-
sif et al., 2001)
Smith-Lemli-Opitz Syn-
drome (Shefer et al.,
1995)
APOA1 11q23.3 Yes Yes Yes Yes
APOA4
APOC3
SC5DL 11q23.3 Stillborn and with
decreased cholesterol
levels (Krakowiak et al.,
2003)
Lathosterolosis (Krakowiak
et al., 2003)
SORL1 11q23.3
(Continued)
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Table 2 | Continued
Gene Locus Previous
GWAS
(HDL)
Previous
GWAS
(LDL/TG)
Teslovich
GWAS
(HDL)
Teslovich
GWAS
(LDL/TG)
Knockout
mouse
phenotype
Candidate
gene
association
Medelian
lipid
disorders
SOAT2 12q13.13 Reduced cholesterol ester
synthesis (Willner et al.,
2003)
Chen et al. (2009)
MVK 12q24.11 Yes Yes
SCARB1 12q24.31 Yes Abnormal HDLs (Miettinen
et al., 2001) Roberts et al.
(2007)
EBPL 13q14.2
NPC2 14q24.3
CYP46A1 14q32.2
LIPC 15q21.3 Yes Yes Yes Hepatic lipase deﬁciency
(Breckenridge et al., 1982)
CLN6 15q23
CYP11A1 15q24.1
APOB48R 16p11.2
CETP 16q13 Yes Yes Yes CETP deﬁciency (Brown
et al., 1989)
MBTPS1 16q23.3
MVD 16q24.3
SCARF1 17p13.3
SREBF1 17p11.2
STARD3 17q12 Yes Mild defects in cholesterol
metabolism (JAX1)
PCTP 17q23.2
FDXR 17q25.1
NPC1 18q11.2
OSBPL1A 18q11.2
ACAA2 18q21.1
VPS4B 18q21.33
LDLR 19p13.2 Yes Yes Elevated LDL-C (Ishibashi
et al., 1993)
Homozygous familial hyper-
cholesterolemia (Hobbs
et al., 1986)
LIPE 19q13.2 Increased HDL concentra-
tion (Haemmerle et al.,
2002)
APOC1 19q13.31 Yes Yes Yes
APOE Hypercholesterolemia
(Zhang et al., 1992)
APOC2 ApoC2 deﬁciency (Brecken-
ridge et al., 1978)
SOD1 21q22.11
ABCG1 21q22.3 Decreased HDL on high fat
diet (Wiersma et al., 2009)
SEC14L2 22q12.2
APOL2 22q12.3
APOL1 22q12.3
SREBF2 22q13.2
CYB5R3 22q13.2
TSPO 22q13.2
MBTPS2 Xp22.11
EBP Xp11.23
NSDHL Xq28
1http://jaxmice.jax.org/query
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“common-disease/common-variant”paradigm, and consider SNP
and genes together rather than in isolation.
In conclusion, using two distinct GWAS data sets based on
modestly-sized samples ascertained by extremes of a quantitative
trait (HDL-C), we have applied pathway analysis to suggest that
an ensemble of ∼100 genes is collectively associated with HDL-C
levels. A fraction of these genes has already been suggested by
previously published literature and by animal models, lending
strong support to the validity of the pathway-based approach. Our
results therefore conﬁrm the validity and potential utility of the
pathway association approach as applied to the extreme tails of a
quantitative trait.
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